Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 cl… Read more
Neuren Pharmaceuticals Limited (NURPF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.397x
Based on the latest financial reports, Neuren Pharmaceuticals Limited (NURPF) has a cash flow conversion efficiency ratio of 0.397x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($128.31 Million) by net assets ($323.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Neuren Pharmaceuticals Limited - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Neuren Pharmaceuticals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Neuren Pharmaceuticals Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuren Pharmaceuticals Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DANAOS CORP. DL -01
F:DVW1
|
N/A |
|
Hongta Securities Co Ltd
SHG:601236
|
0.070x |
|
Viad Corp
NYSE:VVI
|
0.569x |
|
Tellurian Inc
F:MPLN
|
-0.062x |
|
Jointo Energy Investment Co Ltd Hebei
SHE:000600
|
0.096x |
|
Shanghai Emperor of Cleaning Hi-Tech Co Ltd
SHG:603200
|
0.010x |
|
Sichuan Chengfei Integration Technology Corp Ltd
SHE:002190
|
0.003x |
|
Pfizer Limited
NSE:PFIZER
|
0.156x |
Annual Cash Flow Conversion Efficiency for Neuren Pharmaceuticals Limited (2004–2024)
The table below shows the annual cash flow conversion efficiency of Neuren Pharmaceuticals Limited from 2004 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $363.90 Million | $-11.27 Million | -0.031x | -103.44% |
| 2023-12-31 | $205.21 Million | $184.93 Million | 0.901x | +941.36% |
| 2022-12-31 | $41.59 Million | $3.60 Million | 0.087x | +134.07% |
| 2021-12-31 | $39.25 Million | $-9.97 Million | -0.254x | +23.91% |
| 2020-12-31 | $24.20 Million | $-8.08 Million | -0.334x | +60.56% |
| 2019-12-31 | $13.85 Million | $-11.72 Million | -0.846x | -425.81% |
| 2018-12-31 | $24.67 Million | $6.41 Million | 0.260x | +176.04% |
| 2017-12-31 | $16.36 Million | $-5.59 Million | -0.342x | +88.46% |
| 2016-12-31 | $4.18 Million | $-12.38 Million | -2.959x | -234.75% |
| 2015-12-31 | $14.40 Million | $-12.73 Million | -0.884x | -163.10% |
| 2014-12-31 | $19.08 Million | $-6.41 Million | -0.336x | -6.14% |
| 2013-12-31 | $24.36 Million | $-7.71 Million | -0.317x | +31.96% |
| 2012-12-31 | $6.34 Million | $-2.95 Million | -0.465x | -40.59% |
| 2011-12-31 | $9.45 Million | $-3.13 Million | -0.331x | +59.31% |
| 2010-12-31 | $3.53 Million | $-2.87 Million | -0.813x | -364.34% |
| 2009-12-31 | $7.35 Million | $-1.29 Million | -0.175x | +89.20% |
| 2008-12-31 | $5.57 Million | $-9.04 Million | -1.622x | -6.50% |
| 2007-12-31 | $7.55 Million | $-11.50 Million | -1.523x | -169.10% |
| 2006-12-31 | $16.15 Million | $-9.14 Million | -0.566x | -116.92% |
| 2005-12-31 | $32.16 Million | $-8.39 Million | -0.261x | +37.81% |
| 2004-12-31 | $8.77 Million | $-3.68 Million | -0.420x | -- |